Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

At 89%, the 2-year LRC rate was relatively high in the current subcohort ( Figure 4 a), in which the administration of immunotherapy resulted in a highly significant difference ( Figure 4 b).

also in 132,142 other papers

Moreover, none of the patients treated with total radiation doses > 66 Gy had a relapse ( Supplementary Figure S1 ), which—probably due to the small patient numbers—was not significant but showed a strong trend.

also in 5,725 other papers